209
Views
3
CrossRef citations to date
0
Altmetric
Clinical Trial Report

Management of Cough in Patients with Chronic Obstructive Pulmonary Disease: Results of the Multicenter Randomized Placebo-Controlled Clinical Trial

ORCID Icon, , , , , , , , , , , ORCID Icon, , , , , , ORCID Icon & ORCID Icon show all
Pages 1243-1253 | Published online: 05 May 2021

References

  • Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD; 2020 [Internet]. Available from: https://goldcopd.org/gold-reports/. Accessed December 10, 2019.
  • Miravitlles M, Ribera A. Understanding the impact of symptoms on the burden of COPD. Respir Res. 2017;18(1):67. doi:10.1186/s12931-017-0548-3
  • Jones PW, Brusselle G, Dal Negro RW, et al. Patient-centred assessment of COPD in primary care: experience from a cross-sectional study of health-related quality of life in Europe. Prim Care Respir J. 2012;21(3):329–336. doi:10.4104/pcrj.2012.00065
  • Global Initiative for Chronic Obstructive Lung Disease. World lung day; September 25, 2019. Available from: https://goldcopd.org/world-lung-day-2019-respiratory-groups-unite-to-call-for-healthy-lungs-for-all/. Accessed April 16, 2021.
  • Wacker ME, Kitzing K, Jörres RA, et al. The contribution of symptoms and comorbidities to the economic impact of COPD: an analysis of the German COSYCONET cohort. Int J Chronic Obstr Pulm Dis. 2017;12:3437. doi:10.2147/COPD.S141852
  • Miravitlles M, Worth H, Soler Cataluna JJ, et al. Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS Study. Respir Res. 2014;15(1):122. doi:10.1186/s12931-014-0122-1
  • Chuchalin AG, Abrosimov VN, Cough M. GEOTAR-media; 2016:160. (in Russ).
  • Epstein O. The spatial homeostasis hypothesis. Symmetry. 2018;10(4):103. doi:10.3390/sym10040103
  • Tarasov SA, Gorbunov EA, Don ES, et al. Insights into the mechanism of action of highly diluted biologics. J Immunol. 2020;205(issue 5):1345–1354. doi:10.4049/jimmunol.2000098
  • Rafalsky V, Averyanov A, Bart B, et al. Efficacy and safety of Ergoferon versus oseltamivir in adult outpatients with seasonal influenza virus infection: a multicenter, open-label, randomized trial. Int J Infect Dis. 2016;51:47–55. doi:10.1016/j.ijid.2016.09.002
  • Mkrtumyan A, Romantsova T, Vorobiev S, et al. Efficacy and safety of Subetta add-on therapy in type 1 diabetes mellitus: the results of a multicenter, double-blind, placebo-controlled, randomized clinical trial. Diabetes Res Clin Pract. 2018;142:1–9. doi:10.1016/j.diabres.2018.04.044
  • Pushkar D, Vinarov A, Spivak L, et al. Efficacy and safety of Afalaza in men with symptomatic benign prostatic hyperplasia at risk of progression: a multicenter, double-blind, placebo-controlled, randomized clinical trial. Cent European J Urol. 2018;71(4):427–435. doi:10.5173/ceju.2018.1803
  • Instruction for medical use, Rengalin; 2020. Available from: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=f60f62e6-18b2-43f2-83e4-1c97742f0eba&t=. Accessed April 20, 2020.
  • Hsu JY, Stone RA, Logan-Sinclair RB, Worsdell M, Busst CM, Chung KF. Coughing frequency in patients with persistent cough: assessment using a 24 hour ambulatory recorder. Eur Respir J. 1994;7(7):1246–1253. doi:10.1183/09031936.94.07071246
  • Eccles R. The powerful placebo effect in сough: relevance to treatment and clinical trials. Lung. 2020;198(1):13–21. doi:10.1007/s00408-019-00305-5
  • Smith J, Woodcock A. Cough and its importance in COPD. Int J Chron Obstruct Pulmon Dis. 2006;1(3):305–314. doi:10.2147/copd.2006.1.3.305
  • Burgel P-R. Chronic cough and sputum production: a clinical COPD phenotype? Eur Respir J. 2012;40(1):4–6. doi:10.1183/09031936.00022412
  • Koo HK, Park SW, Park JW, et al. Chronic cough as a novel phenotype of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2018;13:1793–1801. doi:10.2147/COPD.S153821
  • Calverley PM. Calverley: cough in chronic obstructive pulmonary disease: is it important and what are the effects of treatment? Cough. 2013;9(1):17. doi:10.1186/1745-9974-9-17
  • Dal Negro RW, Wedzicha JA, Iversen M, et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE Study. Eur Respir J. 2017;50(4):1700711. doi:10.1183/13993003.00711-2017
  • Rogliani P, Matera MG, Page C, Puxeddu E, Cazzola M, Calzetta L. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. Respir Res. 2019;20(1):104. doi:10.1186/s12931-019-1078-y
  • Poole P, Chong J, Cates CJ. CD001287 Cochrane database of systematic reviews. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2019. doi:10.1002/14651858.CD001287
  • Chikina SY. Cough hypersensitivity syndrome. Pulmonology. 2015;25(2):224–228. ( in Russ). doi:10.18093/0869-0189-2015-25-2-224-228
  • Belvisi MG, Birrell MA, Khalid S, et al. Neurophenotypes in airway diseases. Insights from translational cough studies. Am J Respir Crit Care Med. 2016;193(12):1364–1372. doi:10.1164/rccm.201508-1602OC